Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study

Nikesh Dattani; Joseph Shalhoub; Sandip Nandhra; Tristan Lane; Abdulsalam Abu-Own; Ahmed Elbasty; Aled Jones; Andrew Duncan; Andrew Garnham; Ankur Thapar; Anna Murray; Anzar Baig; Athanasios Saratzis; Atif Sharif; Bella Huasen; Claire Dawkins; Craig Nesbitt; Daniel Carradice; Darren Morrow; David Bosanquet; Eamon Kavanagh; Faisal Shaikh; Gergely Gosi; Graeme Ambler; Gregory Fulton; Gurdas Singh; Hannah Travers; Hayley Moore; James Olivier; Louise Hitchman; Martin O’Donohoe; Matthew Popplewell; Mekki Medani; Michael Jenkins; Mingzheng A. Goh; Oliver Lyons; Olivia McBride; Paul Moxey; Philip Stather; Phillipa Burns; Rachel Forsythe; Rachel Sam; Ranjeet Brar; Robert Brightwell; Ruth Benson; Sarah Onida; Sharath Paravastu; Simon Lambracos; Srinivasa R. Vallabhaneni; Stewart Walsh; The Vascular and Endovascular Research Network (VERN) collaborators

doi:10.1177/0268355520936420

Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study

Nikesh Dattani, Joseph Shalhoub, Sandip Nandhra, Tristan Lane, Abdulsalam Abu-Own, Ahmed Elbasty, Aled Jones, Andrew Duncan, Andrew Garnham, Ankur Thapar, Anna Murray, Anzar Baig, Athanasios Saratzis, Atif Sharif, Bella Huasen, Claire Dawkins, Craig Nesbitt, Daniel Carradice, Darren Morrow, David BosanquetEamon Kavanagh, Faisal Shaikh, Gergely Gosi, Graeme Ambler, Gregory Fulton, Gurdas Singh, Hannah Travers, Hayley Moore, James Olivier, Louise Hitchman, Martin O’Donohoe, Matthew Popplewell, Mekki Medani, Michael Jenkins, Mingzheng A. Goh, Oliver Lyons, Olivia McBride, Paul Moxey, Philip Stather, Phillipa Burns, Rachel Forsythe, Rachel Sam, Ranjeet Brar, Robert Brightwell, Ruth Benson, Sarah Onida, Sharath Paravastu, Simon Lambracos, Srinivasa R. Vallabhaneni, Stewart Walsh, The Vascular and Endovascular Research Network (VERN) collaborators

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Objectives: Venous thromboembolism is a potentially fatal complication of superficial endovenous treatment. Proper risk assessment and thromboprophylaxis could mitigate this hazard; however, there are currently no evidence-based or consensus guidelines. This study surveyed UK and Republic of Ireland vascular consultants to determine areas of consensus. Methods: A 32-item survey was sent to vascular consultants via the Vascular and Endovascular Research Network (phase 1). These results generated 10 consensus statements which were redistributed (phase 2). ‘Good’ and ‘very good’ consensus were defined as endorsement/rejection of statements by '67% and '85% of respondents, respectively. Results: Forty-two consultants completed phase 1. This generated seven statements regarding risk factors mandating peri-procedural pharmacoprophylaxis and three statements regarding specific pharmacoprophylaxis regimes. Forty-seven consultants completed phase 2. Regarding venous thromboembolism risk factors mandating pharmacoprophylaxis, ‘good’ and ‘very good’ consensus was achieved for 5/7 and 2/7 statements, respectively. Regarding specific regimens, ‘very good’ consensus was achieved for 3/3 statements. Conclusions: The main findings from this study were that there was ‘good’ or ‘very good’ consensus that patients with any of the seven surveyed risk factors should be given pharmacoprophylaxis with low-molecular-weight heparin. High-risk patients should receive one to two weeks of pharmacoprophylaxis rather than a single dose.

Original language	English
Pages (from-to)	706-714
Number of pages	9
Journal	Phlebology
Volume	35
Issue number	9
Early online date	1 Jul 2020
DOIs	https://doi.org/10.1177/0268355520936420
Publication status	Published - Oct 2020

Keywords

Deep vein thrombosis
varicose veins
venous thromboembolism
VTE management

Access to Document

10.1177/0268355520936420

Cite this

Dattani, N., Shalhoub, J., Nandhra, S., Lane, T., Abu-Own, A., Elbasty, A., Jones, A., Duncan, A., Garnham, A., Thapar, A., Murray, A., Baig, A., Saratzis, A., Sharif, A., Huasen, B., Dawkins, C., Nesbitt, C., Carradice, D., Morrow, D., ... The Vascular and Endovascular Research Network (VERN) collaborators (2020). Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study. Phlebology, 35(9), 706-714. https://doi.org/10.1177/0268355520936420

@article{4c9033341aad436b817ed70233dcecfe,

title = "Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study",

abstract = "Objectives: Venous thromboembolism is a potentially fatal complication of superficial endovenous treatment. Proper risk assessment and thromboprophylaxis could mitigate this hazard; however, there are currently no evidence-based or consensus guidelines. This study surveyed UK and Republic of Ireland vascular consultants to determine areas of consensus. Methods: A 32-item survey was sent to vascular consultants via the Vascular and Endovascular Research Network (phase 1). These results generated 10 consensus statements which were redistributed (phase 2). {\textquoteleft}Good{\textquoteright} and {\textquoteleft}very good{\textquoteright} consensus were defined as endorsement/rejection of statements by '67% and '85% of respondents, respectively. Results: Forty-two consultants completed phase 1. This generated seven statements regarding risk factors mandating peri-procedural pharmacoprophylaxis and three statements regarding specific pharmacoprophylaxis regimes. Forty-seven consultants completed phase 2. Regarding venous thromboembolism risk factors mandating pharmacoprophylaxis, {\textquoteleft}good{\textquoteright} and {\textquoteleft}very good{\textquoteright} consensus was achieved for 5/7 and 2/7 statements, respectively. Regarding specific regimens, {\textquoteleft}very good{\textquoteright} consensus was achieved for 3/3 statements. Conclusions: The main findings from this study were that there was {\textquoteleft}good{\textquoteright} or {\textquoteleft}very good{\textquoteright} consensus that patients with any of the seven surveyed risk factors should be given pharmacoprophylaxis with low-molecular-weight heparin. High-risk patients should receive one to two weeks of pharmacoprophylaxis rather than a single dose.",

keywords = "Deep vein thrombosis, varicose veins, venous thromboembolism, VTE management",

author = "Nikesh Dattani and Joseph Shalhoub and Sandip Nandhra and Tristan Lane and Abdulsalam Abu-Own and Ahmed Elbasty and Aled Jones and Andrew Duncan and Andrew Garnham and Ankur Thapar and Anna Murray and Anzar Baig and Athanasios Saratzis and Atif Sharif and Bella Huasen and Claire Dawkins and Craig Nesbitt and Daniel Carradice and Darren Morrow and David Bosanquet and Eamon Kavanagh and Faisal Shaikh and Gergely Gosi and Graeme Ambler and Gregory Fulton and Gurdas Singh and Hannah Travers and Hayley Moore and James Olivier and Louise Hitchman and Martin O{\textquoteright}Donohoe and Matthew Popplewell and Mekki Medani and Michael Jenkins and Goh, {Mingzheng A.} and Oliver Lyons and Olivia McBride and Paul Moxey and Philip Stather and Phillipa Burns and Rachel Forsythe and Rachel Sam and Ranjeet Brar and Robert Brightwell and Ruth Benson and Sarah Onida and Sharath Paravastu and Simon Lambracos and Vallabhaneni, {Srinivasa R.} and Stewart Walsh and {The Vascular and Endovascular Research Network (VERN) collaborators}",

year = "2020",

month = oct,

doi = "10.1177/0268355520936420",

language = "English",

volume = "35",

pages = "706--714",

journal = "Phlebology",

issn = "0268-3555",

publisher = "Sage Publications",

number = "9",

}

Dattani, N, Shalhoub, J, Nandhra, S, Lane, T, Abu-Own, A, Elbasty, A, Jones, A, Duncan, A, Garnham, A, Thapar, A, Murray, A, Baig, A, Saratzis, A, Sharif, A, Huasen, B, Dawkins, C, Nesbitt, C, Carradice, D, Morrow, D, Bosanquet, D, Kavanagh, E, Shaikh, F, Gosi, G, Ambler, G, Fulton, G, Singh, G, Travers, H, Moore, H, Olivier, J, Hitchman, L, O’Donohoe, M, Popplewell, M, Medani, M, Jenkins, M, Goh, MA, Lyons, O, McBride, O, Moxey, P, Stather, P, Burns, P, Forsythe, R, Sam, R, Brar, R, Brightwell, R, Benson, R, Onida, S, Paravastu, S, Lambracos, S, Vallabhaneni, SR, Walsh, S & The Vascular and Endovascular Research Network (VERN) collaborators 2020, 'Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study', Phlebology, vol. 35, no. 9, pp. 706-714. https://doi.org/10.1177/0268355520936420

TY - JOUR

T1 - Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study

AU - Dattani, Nikesh

AU - Shalhoub, Joseph

AU - Nandhra, Sandip

AU - Lane, Tristan

AU - Abu-Own, Abdulsalam

AU - Elbasty, Ahmed

AU - Jones, Aled

AU - Duncan, Andrew

AU - Garnham, Andrew

AU - Thapar, Ankur

AU - Murray, Anna

AU - Baig, Anzar

AU - Saratzis, Athanasios

AU - Sharif, Atif

AU - Huasen, Bella

AU - Dawkins, Claire

AU - Nesbitt, Craig

AU - Carradice, Daniel

AU - Morrow, Darren

AU - Bosanquet, David

AU - Kavanagh, Eamon

AU - Shaikh, Faisal

AU - Gosi, Gergely

AU - Ambler, Graeme

AU - Fulton, Gregory

AU - Singh, Gurdas

AU - Travers, Hannah

AU - Moore, Hayley

AU - Olivier, James

AU - Hitchman, Louise

AU - O’Donohoe, Martin

AU - Popplewell, Matthew

AU - Medani, Mekki

AU - Jenkins, Michael

AU - Goh, Mingzheng A.

AU - Lyons, Oliver

AU - McBride, Olivia

AU - Moxey, Paul

AU - Stather, Philip

AU - Burns, Phillipa

AU - Forsythe, Rachel

AU - Sam, Rachel

AU - Brar, Ranjeet

AU - Brightwell, Robert

AU - Benson, Ruth

AU - Onida, Sarah

AU - Paravastu, Sharath

AU - Lambracos, Simon

AU - Vallabhaneni, Srinivasa R.

AU - Walsh, Stewart

AU - The Vascular and Endovascular Research Network (VERN) collaborators

PY - 2020/10

Y1 - 2020/10

N2 - Objectives: Venous thromboembolism is a potentially fatal complication of superficial endovenous treatment. Proper risk assessment and thromboprophylaxis could mitigate this hazard; however, there are currently no evidence-based or consensus guidelines. This study surveyed UK and Republic of Ireland vascular consultants to determine areas of consensus. Methods: A 32-item survey was sent to vascular consultants via the Vascular and Endovascular Research Network (phase 1). These results generated 10 consensus statements which were redistributed (phase 2). ‘Good’ and ‘very good’ consensus were defined as endorsement/rejection of statements by '67% and '85% of respondents, respectively. Results: Forty-two consultants completed phase 1. This generated seven statements regarding risk factors mandating peri-procedural pharmacoprophylaxis and three statements regarding specific pharmacoprophylaxis regimes. Forty-seven consultants completed phase 2. Regarding venous thromboembolism risk factors mandating pharmacoprophylaxis, ‘good’ and ‘very good’ consensus was achieved for 5/7 and 2/7 statements, respectively. Regarding specific regimens, ‘very good’ consensus was achieved for 3/3 statements. Conclusions: The main findings from this study were that there was ‘good’ or ‘very good’ consensus that patients with any of the seven surveyed risk factors should be given pharmacoprophylaxis with low-molecular-weight heparin. High-risk patients should receive one to two weeks of pharmacoprophylaxis rather than a single dose.

AB - Objectives: Venous thromboembolism is a potentially fatal complication of superficial endovenous treatment. Proper risk assessment and thromboprophylaxis could mitigate this hazard; however, there are currently no evidence-based or consensus guidelines. This study surveyed UK and Republic of Ireland vascular consultants to determine areas of consensus. Methods: A 32-item survey was sent to vascular consultants via the Vascular and Endovascular Research Network (phase 1). These results generated 10 consensus statements which were redistributed (phase 2). ‘Good’ and ‘very good’ consensus were defined as endorsement/rejection of statements by '67% and '85% of respondents, respectively. Results: Forty-two consultants completed phase 1. This generated seven statements regarding risk factors mandating peri-procedural pharmacoprophylaxis and three statements regarding specific pharmacoprophylaxis regimes. Forty-seven consultants completed phase 2. Regarding venous thromboembolism risk factors mandating pharmacoprophylaxis, ‘good’ and ‘very good’ consensus was achieved for 5/7 and 2/7 statements, respectively. Regarding specific regimens, ‘very good’ consensus was achieved for 3/3 statements. Conclusions: The main findings from this study were that there was ‘good’ or ‘very good’ consensus that patients with any of the seven surveyed risk factors should be given pharmacoprophylaxis with low-molecular-weight heparin. High-risk patients should receive one to two weeks of pharmacoprophylaxis rather than a single dose.

KW - Deep vein thrombosis

KW - varicose veins

KW - venous thromboembolism

KW - VTE management

UR - http://www.scopus.com/inward/record.url?scp=85088962211&partnerID=8YFLogxK

U2 - 10.1177/0268355520936420

DO - 10.1177/0268355520936420

M3 - Article

AN - SCOPUS:85088962211

VL - 35

SP - 706

EP - 714

JO - Phlebology

JF - Phlebology

SN - 0268-3555

IS - 9

ER -

Reducing the risk of venous thromboembolism following superficial endovenous treatment: A UK and Republic of Ireland consensus study

Abstract

Keywords

Access to Document

Other files and links

Cite this